2022
- 07Granted Orphan Drug Designation (ODD) from FDA for NT-I7 in the treatment of glioblastoma multiforme
- 03One-year distribution compliance period, under Regulation S has been lifted
2020
- 10Announced a clinical collaboration with Roche for TECENTRIQ® (atezolizumab)/NT-I7 combination targeting non-small cell lung cancer (NSCLC)
- 06Granted Orphan Drug Designation (ODD) from FDA for NT-I7 in the treatment of Progressive Multifocal Leukoencephalopathy (PML)
- 04Announced a clinical collaboration with Bristol Myers Squibb (BMS) for OPDIVO® (nivolumab)/ NT-I7 combination targeting gastric cancers
2019
- 12Announced a clinical collaboration with Merck for KEYTRUDA® (pembrolizumab)/ NT-I7 combination targeting solid tumors
- 08NeoImmuneTech Co., Ltd., a wholly owned subsidiary of NIT, was established
- 04Granted Orphan Drug Designation (ODD) from FDA for NT-I7 in the treatment of Idiopathic CD4 lymphocytopenia (ICL)
2018
- 05Established liaison office in Korea
- 03Announced a clinical trial collaboration with Roche for TECENTRIQ® (atezolizumab)/ NT-I7 combination targeting advanced high-risk skin cancers
2017
- 10Headquarters relocated and expanded to 2400 Research Boulevard, Rockville, MD 20850
- 05Granted Orphan Drug Designation (ODD) from EMA for NT-I7 in the treatment of Idiopathic CD4 lymphocytopenia (ICL)
2015
- 06Received development and commercialization rights of NT-I7 (efineptakin alfa, rhIL-7-hyFc) from Genexine in America and Europe
2014
- 10Headquarters relocated to 2200 Research Blvd., Rockville, MD 20850
- 01NeoImmuneTech, Inc. Founded at 20271 Goldenrod Lane Germantown, MD 20876